EUCTR2009-013616-12-FR进行中（未招募）1 期
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group,Multicenter Study of the Efficacy and Safety of Dapoxetine in Men With PrematureEjaculation and Concomitant Erectile Dysfunction Treated With aPhosphodiesterase-5 Inhibitor - COUPLE
Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium0 个研究点目标入组 0 人开始时间: 2010年3月9日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Man =18 years of age with co-existing conditions of ED and PE
- •Must have a clinical diagnosis of ED, which has been made by a clinician, and an
- •IIEF score =21 at screening and baseline to ensure reasonable erectile function during their participation in the study
- •Must, by reported history, meet the following diagnostic criteria for PE, as consistent with the ISSM definition of lifelong PE, for at least 6 months before screening:
- •– Ejaculation, which always or nearly always occurs prior to or within about one
- •minute of vaginal penetration
- •– Inability to delay ejaculation on all or nearly all vaginal penetrations
- •– Negative personal consequences, such as distress, bother, frustration, and/or the
- •avoidance of sexual intimacy.” For the purposes of this study negative personal
- •consequences are defined as distress based on the subject’s response to the
- •Personal Distress” question in the PEP (Attachment 6). A subject must define his
- •distress level as at least moderately”.
- •Premature ejaculation must not be exclusively due to the direct effect of a substance (eg, opioid withdrawal)
- •Must be using a stable regimen of a PDE-5 inhibitor (ie, sildenafil, vardenafil, or
- •tadalafil), as reported by the subject, for the treatment of ED for at least 3 months
- •before screening. A subject is considered to be using a stable regimen of a
- •PDE-5 inhibitor if he has been titrated to a dose that is well tolerated and provides
- •good erectile function (ie, an IIEF score =21), and the same dose has been taken on a prn basis for at least 3 months before screening. Subjects who are taking low daily
- •doses of tadalafil must have been taking the drug at a stable dose (ie, the same dose) for at least 3 months before screening.
- •Must be in a stable, monogamous sexual relationship with the same woman for at
- •least 6 months before screening and plan to maintain this relationship for the duration of the study
- •Subjects with a history of hypertension (including newly diagnosed hypertension)
- •must be adequately treated with a stable antihypertensive medical regimen for at least 2 months before screening.
- •Medically stable on the basis of physical examination, medical history, vital signs,
- •and 12-lead ECG performed at screening. If there are abnormalities, they must be
- •consistent with the underlying illness in the study population.
- •Medically stable on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel (including liver enzymes, other specific tests) are outside the normal reference ranges, the subject may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the subject's source documents and initialed by the investigator.
- •Women (partners) must be:
- •– using oral contraceptives, contraceptive injections, contraceptive patch,
- •intrauterine device, double-barrier method (eg, condoms, diaphragm, or cervical
- •cap, with spermicidal foam, cream, or gel, male partner sterilization) as local
- •regulations permit, or
- •– postmenopausal (for at least 1 year before the subject’s screening visit), or
- •– surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal
- •ligation, or otherwise be incapable of pregnancy), before entry, and must agree to continue to use the same method of contraception throughout the study (ie, if the subject and partne
排除标准
- •Anatomical deformities of the genitals that would significantly impair an erection
- •(eg, Peyronie’s disease)
- •Erectile dysfunction secondary to a spinal cord injury
- •Penile prosthetic surgery
- •Indication by the subject of a significant problem with decreased interest in sexual
- •intercourse or other forms of sexual dysfunction, including inhibited or absent orgasm
- •or ejaculation
- •Sexual partner of the subject has a clinically significant problem of decreased interest in sexual intercourse, painful intercourse, or other form of female sexual dysfunction that has a significant impact on the sexual relationship with the subject
- •Known or suspected hypogonadism, hyperprolactinemia, or untreated or
- •insufficiently treated hypothyroidism
- •Significant pathologic cardiac conditions including but not limited to heart failure
- •(New York Heart Association [NYHA] Class II-IV cardiac disease [see Attachment 7, New York Heart Association Classification of Cardiac Disease, for a description of the classes]), conduction abnormalities (ie, second- or third-degree atrioventricular block or sick sinus syndrome) not treated with a permanent pacemaker, significant (as defined by the treating physician) ischemic heart disease, or significant valvular disease
- •Hypotension, defined as a resting blood pressure <90/50 mmHg at screening
- •History of untreated malignant hypertension, and/or a resting systolic blood pressure >170 mmHg, and/or a resting diastolic blood pressure of >100 mmHg
- •Cerebrovascular accident or myocardial infarction within the previous 6 months
- •History suggestive of syncope
- •Diabetes mellitus that is poorly controlled, in the opinion of the investigator
- •History of or current major psychiatric disorder such as mood disorder, anxiety
- •disorder, schizophrenia, mania, suicidal ideation, other psychotic disorder, or
- •Meet the DSM-IV-TR diagnosis, in the opinion of the investigator, for a current
- •depressive or anxiety disorder or received treatment (whether pharmacotherapy
- •and/or psychotherapy) for a depressive or anxiety disorder within the past 2 years
- •Positive diagnosis, based on investigator assessment of depressive or anxiety
- •disorder, dysthymia, suicidality, (hypo) manic episode, panic disorder, agoraphobia,
- •social phobia, obsessive-compulsive disorder, posttraumatic stress disorder, alcohol
- •abuse and dependence, non-alcohol psychoactive substance use disorder, or psychotic disorders
- •History, or suspicion of the use of illicit or recreational drugs
- •Known history of moderate to severe renal impairment (including dialysis) or hepatic impairment (ie, serum creatinine >1.5 times [x] the upper limit of normal [ULN], alanine aminotransferase [ALT] >1.5x ULN, aspartate aminotransferase [AST]
- •>1.5x ULN, total bilirubin >1.25x ULN)
- •Twelve-lead ECG shows significant pathology (in the judgment of the investigator),
- •at screening
- •History of, or currently experiencing any of the following:
- •– Medical events such as surgical interventions (eg, pelvic/retroperitoneal surgery),
- •neurologic conditions (eg, multiple sclerosis), trauma (eg, spinal cord injury), or
- •infections (eg, chronic prostatitis) that are associated with the onset of PE
- •symptoms and considered a potential cause of PE
- •– Bleeding disorder or retinitis pigmentosa
- •– Hepatitis B or C, or human immunodeficiency virus (HIV)
- •– Clinically significant medical or psychiatric problems, or other organ abnormality
- •or pathology for whom, in the opinion of the investigator, th
研究者
相似试验
进行中（未招募）
1 期
A study to test the safety and effectiveness of Bay 41-6551 as additional therapy to standard of care antimicrobial treatment in patients who have Gram-Negative Pneumonia and are intubated and mechanially ventilated.Gram-negative pneumoniaMedDRA version: 17.1Level: LLTClassification code 10035701Term: Pneumonia gram-negative bacterial NOSSystem Organ Class: 100000004862EUCTR2008-000906-35-BEBayer Healthcare AG662
进行中（未招募）
1 期
A study to test the safety and effectiveness of Bay 41-6551 as additional therapy to standard of care antimicrobial treatment in patients who have Gram-Negative Pneumonia and are intubated and mechanially ventilated.Gram-negative pneumoniaMedDRA version: 20.1 Level: LLT Classification code 10035701 Term: Pneumonia gram-negative bacterial NOS System Organ Class: 100000004862EUCTR2008-000906-35-PTBayer AG712
进行中（未招募）
1 期
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients with Gram-Negative PneumoniaGram-negaive pneumoniaEUCTR2008-000906-35-CZBayer Schering Pharma AG712
进行中（未招募）
1 期
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients with Gram-Negative PneumoniaGram-negaive pneumoniaMedDRA version: 9.1 Level: LLT Classification code 10035701 Term: Pneumonia gram-negative bacterial NOSEUCTR2008-000906-35-LVBayer Schering Pharma712
进行中（未招募）
1 期
A study to test the safety and effectiveness of Bay 41-6551 as additional therapy to standard of care antimicrobial treatment in patients who have Gram-Negative Pneumonia and are intubated and mechanially ventilated.Gram-negative pneumoniaMedDRA version: 20.1Level: LLTClassification code 10035701Term: Pneumonia gram-negative bacterial NOSSystem Organ Class: 100000004862EUCTR2008-000906-35-NLBayer AG362